Abstract
Since the pioneering reports describing continuous ambulatory peritoneal dialysis (CAPD) as a novel dialytic therapy (1, 2), it has become an accepted therapeutic modality for patients with end stage renal disease (ESRD). Because of its relative technical simplicity and compatibility with home dialysis, CAPD rapidly has become a suitable therapy for children, particularly small infants (3). Aspects pertaining to mineral metabolism and renal osteodystrophy (ROD) are of particular interest in the pediatric population, and require careful scrutiny in order to fully assess the potential benefits of CAPD.